CERO THERAPEUTICS HOLDINGS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
CERO THERAPEUTICS HOLDINGS, INC. (CERO) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$461.46 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-14
- CERO THERAPEUTICS HOLDINGS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2023-12-31 was $5.61K.
- CERO THERAPEUTICS HOLDINGS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2023-09-30 was -$86.16K.
- CERO THERAPEUTICS HOLDINGS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2023-06-30 was -$112.31K.
- CERO THERAPEUTICS HOLDINGS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2023-03-31 was -$4.90K.
- CERO THERAPEUTICS HOLDINGS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$197.76K.
- CERO THERAPEUTICS HOLDINGS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$254.83K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 1 month | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 4 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 7 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$461.46K 10-Q · filed 2026-08-14 | ||||||
| 2025-06-30 | $169.14K 10-Q · filed 2026-08-14 | ||||||
| 2023-12-31 | $5.61K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-02 | -$80.55K derived: sum of 2 quarters · filed 2024-04-02 | -$192.87K derived: sum of 3 quarters · filed 2024-04-02 | -$197.76K 10-K · filed 2024-04-02 | |||
| 2023-09-30 | -$86.16K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$198.48K derived: sum of 2 quarters · filed 2023-11-09 | -$203.37K 10-Q · filed 2023-11-09 | -$276.74K derived: sum of 4 quarters · filed 2024-04-02 | |||
| 2023-06-30 | -$112.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$117.21K 10-Q · filed 2023-08-14 | -$190.58K derived: sum of 3 quarters · filed 2024-04-02 | -$271.62K derived: sum of 4 quarters · filed 2024-04-02 | |||
| 2023-03-31 | -$4.90K 10-Q · filed 2023-05-12 | -$78.27K derived: sum of 2 quarters · filed 2024-04-02 | -$159.31K derived: sum of 3 quarters · filed 2024-04-02 | -$239.63K derived: sum of 4 quarters · filed 2024-04-02 | |||
| 2022-12-31 | -$73.37K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-02 | -$154.41K derived: sum of 2 quarters · filed 2024-04-02 | -$234.73K derived: sum of 3 quarters · filed 2024-04-02 | -$254.83K 10-K · filed 2024-04-02 | |||
| 2022-09-30 | -$81.04K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$161.36K derived: sum of 2 quarters · filed 2023-11-09 | -$181.46K 10-Q · filed 2023-11-09 | ||||
| 2022-06-30 | -$80.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$100.42K 10-Q · filed 2023-08-14 | |||||
| 2022-03-31 | -$20.10K 10-Q · filed 2023-05-12 | ||||||
| 2021-12-31 | $463.15K 10-K · filed 2023-03-24 | ||||||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-10 | ||||||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |